

Jean-Mathieu Beauregard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8197357/publications.pdf>

Version: 2024-02-01

54
papers

1,450
citations

304743

22
h-index

330143

37
g-index

56
all docs

56
docs citations

56
times ranked

1810
citing authors

#	ARTICLE	IF	CITATIONS
1	The Tripleâ€Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. <i>BJU International</i> , 2022, 130, 314-322.	2.5	6
2	Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 424-426.	6.4	2
3	Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254656.	5.0	28
4	Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 42.	6.2	13
5	¹⁸ F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. <i>Canadian Urological Association Journal</i> , 2021, 15, 301-307.	0.6	5
6	Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With ¹⁷⁷ Lu-DOTATATE: A Case Report. <i>Frontiers in Endocrinology</i> , 2021, 12, 705271.	3.5	2
7	PSMA Theranostics: Current Landscape and Future Outlook. <i>Cancers</i> , 2021, 13, 4023.	3.7	33
8	Role of Artificial Intelligence in Theranostics. <i>PET Clinics</i> , 2021, 16, 627-641.	3.0	12
9	Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of ¹⁷⁷ Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. <i>Cancers</i> , 2021, 13, 232.	3.7	15
10	Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems. <i>EJNMMI Physics</i> , 2021, 8, 73.	2.7	2
11	Optimizing the Schedule of PARP Inhibitors in Combination with ¹⁷⁷ Lu-DOTATATE: A Dosimetry Rationale. <i>Biomedicines</i> , 2021, 9, 1570.	3.2	4
12	Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 907-921.	6.4	21
13	Impact of dead time on quantitative ¹⁷⁷ Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. <i>EJNMMI Physics</i> , 2020, 7, 32.	2.7	11
14	Posterior Cingulate Cortex Hypometabolism in Non-Amnesic Variants of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1569-1577.	2.6	7
15	GLUT1 expression in high-risk prostate cancer: correlation with ¹⁸ F-FDG-PET/CT and clinical outcome. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 441-448.	3.9	36
16	Comprehensive SPECT/CT system characterization and calibration for ¹⁷⁷ Lu quantitative SPECT (QSPECT) with dead-time correction. <i>EJNMMI Physics</i> , 2020, 7, 10.	2.7	18
17	GLUT1 expression in high-risk prostate cancer: Correlation with ¹⁸ F-FDG-PET/CT and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2020, 38, 291-291.	1.6	0
18	Personalized kidney dosimetry in ¹⁷⁷ Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations. <i>Physics in Medicine and Biology</i> , 2019, 64, 175004.	3.0	8

#	ARTICLE	IF	CITATIONS
19	Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a ¹⁷⁷ Lu-DOTATATE patient study. <i>Physics in Medicine and Biology</i> , 2019, 64, 175006.	3.0	26
20	Feasibility of Intraprostatic Prostate Cancer Imaging with FCH-PET/CT for Preoperative Planning of Image-Guided HDR Brachytherapy. <i>Brachytherapy</i> , 2019, 18, S72.	0.5	0
21	Personalized ¹⁷⁷ Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 728-742.	6.4	109
22	Increased Prostate Cancer Glucose Metabolism Detected by ¹⁸ F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. <i>European Urology Focus</i> , 2019, 5, 998-1006.	3.1	25
23	Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes. <i>EJNMMI Physics</i> , 2018, 5, 8.	2.7	37
24	Neuroradiological and Neuropathological Changes After ¹⁷⁷ Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma. <i>Operative Neurosurgery</i> , 2018, 15, 100-109.	0.8	16
25	Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 359-365.	1.3	11
26	Accuracy and reproducibility of simplified QSPECT dosimetry for personalized ¹⁷⁷ Lu-octreotate PRRT. <i>EJNMMI Physics</i> , 2018, 5, 25.	2.7	45
27	Potential of ¹⁷⁷ Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. <i>Oncotarget</i> , 2018, 9, 24693-24706.	1.8	44
28	Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. <i>European Urology Focus</i> , 2017, 3, 639-642.	3.1	15
29	Personalized ¹⁷⁷ Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1490-1500.	6.4	84
30	Accuracy of ¹⁷⁷ Lu activity quantification in SPECT imaging: a phantom study. <i>EJNMMI Physics</i> , 2017, 4, 2.	2.7	46
31	A CZT-based blood counter for quantitative molecular imaging. <i>EJNMMI Physics</i> , 2017, 4, 18.	2.7	3
32	How we read FCH-PET/CT for prostate cancer. <i>Cancer Imaging</i> , 2016, 16, 41.	2.8	5
33	Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1251-1262.	2.6	44
34	Clinical Outcomes in Patients Treated with Selective HDR Image-Guided Boost to Dominant Intra-Prostatic Lesion. <i>Brachytherapy</i> , 2016, 15, S52.	0.5	1
35	Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 695-705.	2.6	13
36	Reversal of Severe and Refractory Humoral Hypercalcemia With ¹⁷⁷ Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas. <i>Clinical Nuclear Medicine</i> , 2015, 40, e448-e450.	1.3	3

#	ARTICLE	IF	CITATIONS
37	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. <i>Cancer Imaging</i> , 2015, 15, 2.	2.8	47
38	New developments in the imaging of metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 265-270.	1.3	7
39	Sci-Thur AM: YIS - 03: irtGPUMCD: a new GPU-calculated dosimetry code for 177 Lu-octreotate radionuclide therapy of neuroendocrine tumors. <i>Medical Physics</i> , 2014, 41, 1-1.	3.0	1
40	Sci-Thur PM: Imaging - 05: Calibration of a SPECT/CT camera for quantitative SPECT with 99m Tc. <i>Medical Physics</i> , 2014, 41, 4-4.	3.0	0
41	Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1853-1860.	6.4	32
42	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. <i>Nuclear Medicine Communications</i> , 2013, 34, 521-526.	1.1	5
43	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. <i>Medical Physics</i> , 2013, 40, 112503.	3.0	66
44	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 971-976.	1.3	53
45	The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 50-56.	6.4	119
46	⁶⁸ Ga PET/CT Ventilation-Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1513-1519.	5.0	87
47	Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. <i>Cancer Imaging</i> , 2011, 11, 56-66.	2.8	111
48	A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors. <i>Molecular Imaging and Biology</i> , 2011, 13, 518-525.	2.6	5
49	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 991-1001.	6.4	34
50	ORIGINAL ARTICLE: Pilot comparison of ¹⁸ F-fluorocholine and ¹⁸ F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2010, 54, 325-332.	1.8	56
51	Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11 ^β -Methoxy-16 ^α - ¹⁸ F-Fluoroestradiol Using Serial Whole-Body PET/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 100-107.	5.0	36
52	[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1473-1479.	6.4	22
53	Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES. <i>Nuclear Medicine and Biology</i> , 2007, 34, 325-329.	0.6	10
54	Steroid Receptor Imaging in Breast Cancer. <i>PET Clinics</i> , 2006, 1, 51-70.	3.0	9